Where Cross-Organ Insight Drives Better Antifibrotic Development Decisions

The 10th Antifibrotic Drug Development Summit is the industry-focused forum for teams navigating the scientific and translational complexity of fibrosis drug development. Bringing together experts across lung, liver, kidney, cardiac, skin, gastrointestinal, and systemic fibrotic diseases, the summit examines where pathogenic mechanisms converge across organs and where indication-specific biology requires a tailored development strategy.

With a program spanning discovery through early clinical development, attendees will gain practical insight into identifying disease-driving targets, selecting human-relevant models, designing translational evidence packages, and building biomarker strategies that can demonstrate antifibrotic activity earlier, helping teams prioritize the right assets, generate more decision-enabling evidence, and determine where learnings from one fibrotic indication can strengthen or accelerate development in another.

The agenda will also explore how single-cell technologies are revealing previously hidden pathogenic cell states, how mechanobiology may unlock new routes to fibrosis reversal, and how clinical learnings can be translated back into stronger research decisions.

Joined by organizations including Madrigal Pharmaceuticals, AbbVie, Arda Therapeutics, aTyr Pharma, Vicore Pharma, and more, the summit brings the wider fibrosis ecosystem together across three interactive workshops and two main conference days to compare approaches to fibrosis resolution, cross-tissue biology, human-relevant models, patient stratification, and cross-indication expansion.

Find out more: https://ter.li/kaoyrm2t